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ORIGINAL ARTICLE
Background: Hypertension in midlife is associated with increased 
risk of Alzheimer disease and vascular dementia late in life. In 
addition, some antihypertensive drugs have been proposed to have 
cognitive benefits, independent of their effect on hypertension. Con-
sequently, there is potential to repurpose antihypertensive drugs for 
the prevention of dementia. This study systematically compared 
seven antihypertensive drug classes for this purpose, using the Clin-
ical Practice Research Datalink.
Methods: We assessed treatments for hypertension in an instru-
mental variable analysis to address potential confounding and reverse 
causation. We used physicians’ prescribing preference as an ordinal 
instrument, defined by the physicians’ last seven prescriptions. Par-
ticipants considered were new antihypertensive users between 1996 
and 2016, aged 40 and over.
Results: We analyzed 849,378 patients, with total follow up of 
5,497,266 patient-years. We estimated that β-adrenoceptor block-
ers and vasodilator antihypertensives conferred small protective 
effects—for example, β-adrenoceptor blockers were associated with 
13 (95% confidence interval = 6, 20) fewer cases of any dementia per 
1000 treated compared with other antihypertensives.
Conclusions: We estimated small differences in the effects of anti-
hypertensive drug classes on dementia outcomes. We also show that 
the magnitude of the differences between drug classes is smaller than 
that previously reported. Future research should look to implement 
other causal analysis methods to address biases in conventional ob-
servational research, with the ultimate aim of triangulating the evi-
dence concerning this hypothesis.
Keywords: Alzheimer Disease; Antihypertensive Agents; Dementia; 
Drug Repositioning; Drug Repurposing
(Epidemiology 2020;31: 852–859)
There is a substantial unmet clinical need for treatments of dementia, where benefits to patients, society, and the 
public purse can be gained. Despite this, some drug com-
panies have withdrawn from this therapy area due to failed 
and costly efforts to find new treatments.1 Drug repurpos-
ing, the identification of existing compounds for other clin-
ical conditions, offers substantial advantages over traditional 
drug-discovery approaches. This includes immediate access 
to human safety data from the original clinical development 
work, which can accelerate testing in clinical trials, saving 
both time and money.2 Many antihypertensives have been 
proposed as drug-repurposing candidates for dementia pre-
vention, in part because of research to better understand the 
observed associations between midlife hypertension and later-
life risk of Alzheimer disease and vascular dementia.3–6 Vas-
cular dysregulation may also have a pathological role early 
in the development of Alzheimer disease.7 Finally, there have 
been suggestions that some antihypertensives, specifically 
those that block angiotensin receptor and calcium-channel 
signaling, may have other neurological benefits.7–9 Several ob-
servational studies have previously investigated repurposing 
antihypertensives for dementia prevention, but non-genetic 
instrumental variable analysis has not been applied in this 
setting.10–17
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Instrumental variable analysis, which estimates the 
causal effect of an exposure on an outcome by using a third 
variable (the instrument), can be robust to confounding and 
reverse causation if certain assumptions are met (Figure 1). 
That is, the instrument must (1) be associated with the ex-
posure of interest; (2) affect the outcome only through its 
effect on the exposure; and (3) have no common causes with 
the outcome (i.e., no confounders of the instrument–out-
come association).18,19 Physicians’ prescribing preference 
has been proposed as an instrumental variable in pharmaco-
epidemiology.20–24 It meets the instrument conditions, as (1) 
it is associated with the prescription issued by the physician; 
(2) it is unlikely to relate to the patient’s risk of dementia 
other than through the prescription issued; and (3) physi-
cians’ prescribing preference is unlikely to share a cause 
with the patient’s outcome because patients have relatively 
little choice over which physician they see or knowledge 
of their physicians’ preferences for antihypertensive drug 
classes.22 The last condition is likely to hold in the UK set-
ting used for this study because prior to 5 January 2015, 
patients were required to live within a practice’s boundary 
area to register at that practice, which limited their choice of 
physician.25 We therefore report a systematic assessment of 
antihypertensive drug classes as candidates for the preven-
tion of dementia, using physicians’ prescribing preference 




We conducted a prospective new-user cohort study in 
the CPRD, a primary-care database with over 11.3 million 
people from more than 670 UK practices.26,27 The data were 
extracted from the CPRD-GOLD primary-care dataset March 
2016 snapshot. This snapshot included all patients, with data 
that met a minimum standard of quality set by the CPRD, who 
registered at a participating practice from 1 January 1987 to 
29 February 2016.28 The a priori protocol was published prior 
to study commencement (see eText 1; http://links.lww.com/
EDE/B711 for amendments), and the study design diagram 
is included as eFigure 1; http://links.lww.com/EDE/B711.29 
The protocol for this study was approved by the CPRD’s In-
dependent Scientific Advisory Committee (ISAC 15_246R). 
This study did not directly involve patients; so further ethical 
approval was not required.
Participants
Patients were included in the analysis if they were aged 
40 years or over and received a first prescription for an antihy-
pertensive drug class of interest. We stopped follow-up at the 
earliest of a dementia outcome; death; end of registration at a 
CPRD practice; or the end of follow-up (29 February 2016). 
Patients were excluded if they were of unknown gender; had 
less than 12 months of good-quality data prior to their first 
prescription; or were initially prescribed multiple antihyper-
tensive drug classes. We also excluded patients who were pre-
scribed an antihypertensive before January 1996, as 1996 was 
the first complete year in which all of the drugs being consid-
ered were available.
Exposures
We considered seven antihypertensive drug classes 
based on the British National Formulary groupings.30 These 
were α-adrenoceptor blockers, angiotensin-converting enzyme 
inhibitors, angiotensin II receptor blockers, β-adrenoceptor 
blockers, calcium-channel blockers, diuretics (either “thia-
zides and related diuretics” or “potassium-sparing diuretics 
and aldosterone antagonists”), and vasodilator antihyperten-
sives. To mimic a randomized controlled trial (RCT), we ana-
lyzed exposure in an intention-to-treat framework, i.e., based 
on the first prescription irrespective of treatment discontinu-
ation or subsequent switches to, or additions of, other drug 
classes.31 The index date for each patient was the date of first 
prescription for an antihypertensive drug. We did not model 
treatment switching, as it was likely to be nonrandom and con-
founded by patients’ unobservable characteristics.
Figure 1. Directed acyclic graph for the instrumental variable analysis model.
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Outcomes
Our primary outcome was dementia. We also de-
fined four subtypes: probable Alzheimer disease, possible 
Alzheimer disease, vascular dementia, and other dementias 
(eFigure 2; http://links.lww.com/EDE/B711), which we con-
sidered as a sensitivity analysis.
Covariates
We adjusted the instrumental variable analysis for pre-
scription year, as antihypertensive prescriptions have varied by 
year; so this may have influenced both the instrument–expo-
sure and instrument–outcome associations. We assumed that 
other potential covariates influenced the exposure–outcome 
association but not the instrument–exposure or instrument–
outcome associations, and so are expected to be balanced 
across levels of the instrument if the instrument assumptions 
are met. The instrumental variable analysis was compared 
with a multivariable logistic regression analysis to assess the 
extent of confounding. The multivariable logistic regression 
analysis was adjusted for prescription year; sex; age at index; 
previous history of coronary heart disease, coronary bypass 
surgery, or cerebrovascular disease; chronic disease; socioec-
onomic position; consultation rate; alcohol status; smoking 
status; and body mass index. All covariates were determined 
prior to index, and they are defined fully in eText 2; http://
links.lww.com/EDE/B711. We imputed missing data in the 
covariates 20 times using the Imputation by Chained Equa-
tions package in Stata for each analysis dataset.32
Code Lists
We defined prescriptions using Product codes and 
diagnoses using Read codes. These codes are recorded at 
the time of the consultation and uniquely define prescrip-
tions and clinical terms in the CPRD. The code lists for this 
study are provided on GitHub (https://github.com/venexia/
repurposing-antihypertensives-dementia).
Assessment of Bias
We constructed scaled bias component plots using the 
subset of patients with complete covariate information.33,34 
Instrument–covariate associations were scaled by dividing 
the coefficient by the instrument–exposure association (i.e., 
the first stage regression result). To further assess bias, we re-
peated the analysis adjusting for each covariate, in turn to de-
termine the effect on our results.
Statistical Methods
This study used instrumental variable analysis, with 
physicians-preferred antihypertensive drug class as an instru-
ment to proxy for exposure. We compared each drug class 
against all other antihypertensives. We derived prescribing 
preference from the prescriptions issued by the physician to 
their seven most recent patients who received an antihyper-
tensive.35,36 This resulted in an ordinal instrument, with a min-
imum value of zero and a maximum value of seven, indicating 
how many of the previous prescriptions for antihypertensives 
the physician had chosen the drug class of interest. Seven 
previous prescriptions were selected, as this number has pre-
viously been used in the literature and is thought to balance 
instrument strength, which increases with additional pre-
scriptions, and recent prescribing trends, which are lost with 
additional prescriptions.20 We used the instrument in an or-
dinal form, rather than binary, to further improve instrument 
strength, as ordinal instruments capture more variation in the 
exposure. We calculated robust standard errors and statistics 
to address arbitrary heteroskedasticity and performed cluster-
ing by physician to address both arbitrary heteroskedasticity 
and intra-group correlations between physicians.37 Obtaining 
a point estimate requires a fourth instrument assumption of 
monotonicity or no effect modification by values of the in-
strument.38 Monotonicity assumes that if a patient saw a phy-
sician with a stronger preference for a given drug, they would 
be more likely to receive that drug. No effect modification 
requires that the physicians’ preferences do not modify the 
effects of antihypertensives. Under monotonicity, the results 
were interpreted as the effect among patients whose prescrip-
tion was affected by their physicians’ preference (known as 
the local average treatment effect).39 Under no effect modifi-
cation, the estimates can be interpreted as the effects of treat-
ment in those treated. For each analysis, we present the partial 
F statistic to quantify and test the strength of the instrument–
exposure association and endogeneity test results. Finally, 
we present a corresponding multivariable logistic regression 
analysis. The instrumental variable analysis is presented in 
line with reporting guidelines (eText 3; http://links.lww.com/
EDE/B711).40 All analyses were conducted in Stata version 
15MP (StataCorp, College Station, TX) and R version 3.4.4 
(R Foundation for Statistical Computing, Vienna, Austria).41,42 
Code is available from GitHub (https://github.com/venexia/
repurposing-antihypertensives-dementia).
Sensitivity Analyses
We performed seven sensitivity analyses to assess the 
stability of our results. First, we repeated the main analysis 
using the dementia subtype outcomes to ascertain whether the 
observed effects were being driven by a particular subtype.
Beta-adrenoceptor blockers can be prescribed in low doses 
for the treatment of anxiety.43 To test the effect of removing these 
patients, the second sensitivity analysis removed individuals 
who both received a drug class of interest and had a Read code 
indicating anxiety, or other neurotic, stress-related, and somato-
form disorders in the same consultation.44 The third sensitivity 
analysis also tested this but instead removed individuals whose 
dose was in the bottom 25% for their index drug class.
Differential prescribing occurs in women of child-
bearing age due to risks associated with some antihyper-
tensives during pregnancy.45 This might affect the youngest 
members of the cohort; so the fourth sensitivity analysis re-
stricted the patients to those aged 55 years and over at index, 
as in the Reducing pathology in Alzheimer’s Disease through 
Angiotensin Targeting trial.46
Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Epidemiology • Volume 31, Number 6, November 2020 Antihypertensives for Dementia Prevention
© 2020 Wolters Kluwer Health, Inc. All rights reserved. www.epidem.com | 855
The fifth sensitivity analysis repeated the main analysis, 
with adjustment for the average age and socioeconomic posi-
tion of the past seven patients seen by the physician, i.e., the 
patients used to define the instrument. These factors, particu-
larly age, are strong confounders of our outcome and so may 
have a large impact on our results if incorrectly accounted for.
Our sixth sensitivity analysis also repeated the main 
analysis but with control for prescribing physician fixed 
effects. This model removes time-invariant differences be-
tween physicians, focusing instead on variation present within 
physicians, but can lack precision.47
Using an ordinal instrument could potentially lead to 
over-identification. To test this, we performed a final sen-
sitivity analysis that applied the Sargan–Hansen test to two 
dichotomized instruments. The first instrument took a value 
of one if the treatment of interest was prescribed four or more 
times and a value of zero otherwise. The second instrument 
took a value of one if the treatment of interest was prescribed 
six or more times and a value of zero otherwise.
RESULTS
Patient Characteristics
A total of 849,378 patients, with follow-up of 5,497,266 
patient-years, met the criteria for our analysis. eFigure 3; 
http://links.lww.com/EDE/B711 outlines patient attrition. 
Most patients were excluded for being aged under 40 years 
at index (n = 93458), having less than 12 months’ worth of 
data prior to index (n = 682465), or initially receiving multiple 
antihypertensives (n = 45777). Table presents patient charac-
teristics of those remaining in the cohort.48–50 Of the 849,378 
patients, 410,805 (48%) had complete covariate information. 
Incomplete covariate information was mainly due to missing 
values for the Index of Multiple Deprivation, which was used 
to adjust for socioeconomic position, as this measure is only 
available for patients in English practices. One notable feature 
of the patient characteristics is that 97% of patients receiving 
α-adrenoceptor blockers and 99% of patients receiving vaso-
dilator antihypertensives were men—this difference persists, 
regardless of the age at first prescription (eTable 1; http://
links.lww.com/EDE/B710). We also observed that 32% of 
patients received a prescription for the antihypertensive they 
were initially prescribed 5 or more years after their initial ex-
posure, with some variation in retention based on drug class.
Instrument Evaluation
We tested the independence assumption using the F sta-
tistic and mean instrument–exposure association. Our proposed 
instruments had a minimum F statistic of 4,702 in the main anal-
yses, indicating that weak instrument bias is unlikely to have 
affected the results. Meanwhile, the mean instrument–exposure 
association was calculated to be 0.08 (SD, 0.03; eTable 2; http://
links.lww.com/EDE/B710). We assessed whether we could fal-
sify the independence and exclusion restriction assumptions 
using Bonet’s instrumental variable inequality tests.51–53 The 
inequalities held at each level of the instrument in our main 
analyses (eTable 3; http://links.lww.com/EDE/B710). The inde-
pendence assumption was further assessed using bias compo-
nent plots—see “Assessment of bias” for full details. We could 
not assess whether the monotonicity assumption held because 
there are no established methods for ordinal instruments used to 
proxy binary exposures that we could implement with the avail-
able data (e.g., we could not survey physicians included in this 
analysis).54 Nor is it possible to directly test the no effect mod-
ification assumption. For the assumptions we did assess, esti-
mates based on the instrument may suffer from bias even if they 
did not associate with measured confounders (i.e., unmeasured 
confounding). The distribution of the instrument varied by drug 
class (eFigure 4; http://links.lww.com/EDE/B711). Vasodilator 
antihypertensives and angiotensin II receptor blockers were not 
commonly prescribed; so the instruments used to study them 
tended to favor the comparator.
Primary Analyses
This analysis estimated that β-adrenoceptor blockers 
were protective, resulting in 13 (95% CI = 6, 20) fewer de-
mentia cases when compared with other antihypertensives per 
1000 people treated. Vasodilator antihypertensives also had 
a point estimate consistent with a protective effect; however, 
suffered from much uncertainty  due to only 1% of partici-
pants being exposed to this drug class. Meanwhile, we esti-
mated that diuretics were harmful, resulting in 14 (95% CI 
= 7, 20) additional dementia cases compared with other anti-
hypertensives per 1000 people treated. Instrumental variable 
effect estimates for all drug classes are presented in Figure 2 
and eTable 4; http://links.lww.com/EDE/B710. The results 
of the corresponding multivariable logistic regression using 
imputed data are presented in eFigure 5; http://links.lww.com/
EDE/B711 and eTable 5; http://links.lww.com/EDE/B710. 
Endogeneity tests found little evidence to reject the null that 
the exposure was exogenous, i.e., there was a difference be-
tween the instrumental variable analysis and ordinary least 
squares results (eTable 4; http://links.lww.com/EDE/B710).
Assessment of Bias
Bias component plots were used to assess bias among 
patients using the imputed datasets to account for missing 
covariate information (eFigures 6; http://links.lww.com/EDE/
B711 and 7; http://links.lww.com/EDE/B711). The bias com-
ponent plots suggested that the instrumental variable analysis 
for certain drug classes may have been biased for several of 
the covariates tested. There was also substantial uncertainty 
surrounding some of the scaled instrument–covariate associa-
tions. Repeating the analysis with adjustment for each covari-
ate produced consistent results with the main analysis (eFigure 
8; http://links.lww.com/EDE/B711 and eTable 6; http://links.
lww.com/EDE/B710). The exceptions to this were the results 
concerning α- and β-adrenoceptor blockers after adjust-
ment for age. Patients taking these drug classes had among 
the oldest and youngest median ages at index, respectively 
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(Table), which may explain why they were most affected by 
the adjustment.
Sensitivity Analyses
The dementia subtype analyses revealed some vari-
ation in the effect for some drug classes (eFigure 9; http://
links.lww.com/EDE/B711 and eTable 7; http://links.lww.
com/EDE/B710). For example, diuretics were estimated to 
result in 14 (95% CI = 7, 20) additional cases of dementia 
per 1000 individuals treated but had little effect on vascular 
and other dementias. However, other drug classes, such as 
α-adrenoceptor blockers, were very consistent in their esti-
mated effect on all outcomes. This sensitivity analysis is 
limited by the fact that distinguishing dementia subtypes is 
difficult, and so there is the potential for outcome misclassi-
fication. The other sensitivity analyses also had mixed effects 
across drug classes (eFigure 10; http://links.lww.com/EDE/
B711 and eTable 8; http://links.lww.com/EDE/B710). For in-
stance, results of two of the five sensitivity analyses were con-
cordant with the main analysis for α-adrenoceptor blockers. 
The remaining three sensitivity analyses were suggestive of 
bias by age, as restricting the analysis to those aged 55 years 
and older or including adjustment for age and socioeconomic 
position led the estimates to be discordant with the main anal-
ysis. Despite this, other drug classes, such as the angiotensin-
converting enzyme inhibitors and diuretics, had consistent 
estimates, regardless of the sensitivity analyses performed. 
For the final sensitivity analysis, we performed the Sargan–
Hansen test to assess whether over-identification was likely 
to have affected our results (eTable 9; http://links.lww.com/
EDE/B710). The test found little evidence to suggest this was 
the case, increasing our confidence that the ordinal instrument 
used in this study was appropriate.
DISCUSSION
Principal Findings
We report a systematic assessment of antihypertensive 
drug classes as candidates for the prevention of dementia, 
using physicians’ prescribing preference as an instrument in 



















Sample size 67,360 14,717 195,891 240,864 139,730 180,946 9,870 849,378
Median year of first 
prescription
2008 2005 2007 2005 2008 2003 2008 2006
Male sex 97% (65,365) 55% (8,141) 58% (113.667) 43% (104,096) 49% (68,739) 36% (65,177) 99% (9,796) 51% (434,981)
Median age at first 
prescription
65 59 59 55 64 66 57 61
Previous history of 
coronary artery disease
0.2% (129) 0.6% (85) 0.8% (1536) 0.9% (2056) 0.4% (562) 0.1% (203) 0.1% (11) 0.5% (4582)
Previous history of 
coronary bypass surgery
0.3% (193) 0.3% (45) 0.5% (946) 0.5% (1,262) 0.3% (418) 0.1% (265) 0.1% (14) 0.4% (3,143)
Previous history of 
cerebrovascular disease
2.0% (1,319) 2.1% (311) 3.0% (5,813) 1.4% (3,387) 2.3% (3,194) 2.8% (5,090) 0.7% (73) 2.3% (19,187)
At least one comorbidity 
on the Charlson indexa
37% (24,817) 42% (6,238) 51% (99,492) 26% (62,604) 39% (54,081) 36% (65,212) 43% (4,207) 37% (316,651)
Median Index of Multiple 
Deprivation 2010 scoreb
8 8 9 9 9 9 8 9
Mean annual consultation 
rate (SD)
5.6 (5.4) 6.1 (6.3) 6.1 (6.0) 5.8 (5.3) 5.9 (5.8) 6.0 (5.6) 5.5 (5.1) 5.9 (5.7)
Ever drinkerc 89% (60,070) 85% (12,538) 86% (167,636) 86% (207,457) 85% (118,104) 84% (152,473) 92% (9,059) 86% (727,337)
Ever smokerd 55% (36,691) 53% (7,729) 54% (105,401) 54% (130,894) 53% (74,540) 55% (99,793) 58% (5,688) 54% (460,736)
Mean body mass index 
(standard deviation)e
26.5 (4.2) 28.6 (5.7) 29.0 (5.9) 26.6 (5.0) 27.5 (5.4) 27.5 (5.5) 27.3 (4.4) 27.5 (5.4)
Same antihypertensive  
after 5 y
24% (15,877) 45% (6,575) 34% (66,639) 28% (67,705) 29% (39,879) 39% (70,446) 13% (1,267) 32% (268,388)
aA classification of 17 chronic diseases that may alter mortality risk.
bA proxy for socioeconomic position that is measured as “twentiles” (1 = least deprived and 20 = most deprived). Index of Multiple Deprivation 2010 score was missing for 39% 
(328,233) of the whole sample.
cMissing for 16% (132,387) of the whole sample. For this table, it has been classified as “ever” (i.e., former or current) vs. “never”.
dMissing for 6.4% (54,447) of the whole sample. For this table, it has been classified as “ever” (i.e., former or current) vs. “never”.
eEither calculated from height and weight measurements or provided. Missing for 16% (128,830) of the whole sample.
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the CPRD. In our study, β-adrenoceptor blockers and vaso-
dilator antihypertensives showed negative associations with 
risk of dementia when compared with other antihyperten-
sive drug classes in this study, while diuretics showed a pos-
itive association with risk. Diuretics work by increasing the 
amount of urine produced by the body. Differences in serum 
uric acid—a metabolite removed from the body in urine—
have previously been observed between dementia patients 
and controls, though the evidence as a whole for dementia 
is mixed.55 Vasodilator antihypertensives, which—unlike the 
diuretics—showed an imprecise negative association with the 
risk of dementia outcomes when compared with other antihy-
pertensive drug classes, act on resistance vessels by relaxing 
their vascular smooth muscle.56 Consequently, their effect on 
dementia may be related to increased blood flow and reduced 
vascular burden. An important consideration in the evaluation 
of these drugs, and other antihypertensives, is whether they 
cross the blood–brain barrier, as this is likely to be relevant to 
their utility in dementia prevention.
Comparison with Existing Literature
There have been no RCTs published to date that have 
directly compared antihypertensive drug classes with each 
other for the prevention or treatment of Alzheimer disease. 
However, the Systolic Blood Pressure Intervention Trial - 
Memory and Cognition in Decreased Hypertension trial 
compared the effect of intensive versus standard blood pres-
sure control on probable dementia, mild cognitive impair-
ment, and a composite outcome combining these outcomes. 
The trial, which combined antihypertensive medications, 
found intensive blood pressure control to be beneficial for 
the mild cognitive impairment and composite outcomes. 
It also reported a hazard ratio of 0.83 (95% CI = 0.67, 
1.04) for the probable dementia outcome but suggested 
analysis of this outcome may have been underpowered due to 
the early termination of the trial.
A meta-analysis by Larsson et al.10 identified seven 
prospective observational studies that have compared antihy-
pertensives against each other.10–17 Two of these studies also 
make use of the CPRD (eText 4; http://links.lww.com/EDE/
B711).13,16 Among the studies identified by Larsson et al.10 
Davies et al.13 estimated angiotensin II receptor blockers to 
have a relative risk of 0.55 (95% CI = 0.49, 0.62), and Hwang 
et al.17 estimated calcium-channel blockers to have a rela-
tive risk of 0.81 (95% CI = 0.75, 0.87) when compared with 
other antihypertensives for dementia prevention. These rela-
tive risks correspond to −13 (95% CI = −15, −11) additional 
cases per 1000 for angiotensin II receptor blockers and −6 
(95% CI = −7, −4) for calcium-channel blockers (see eText 5; 
http://links.lww.com/EDE/B711 for estimate conversion).57 
In contrast to this, our analysis estimated that β-adrenoceptor 
blocker and vasodilator antihypertensives were among the 
most protective drug classes when compared with other anti-
hypertensives. The major difference between our study and 
those previously conducted is the statistical methods used. 
When the analysis assumptions are met, instrumental variable 
analysis should not be subject to unmeasured confounding, 
which the other analyses may have been susceptible to.
Limitations
A limitation of this study is we cannot prove that the 
instrumental variable assumptions hold. The only assumption 
that can be empirically tested is relevance, i.e., the instrument 
is associated with the rates of prescribing. Our instruments 
had a minimum F statistic of 4,702 in the main analyses, dem-
onstrating a strong association with the exposure. In addition, 
by defining our instrument using the past seven prescriptions 
as opposed to the last prescription issued, we are potentially 
Figure 2. Instrumental variable estimates for the number of additional cases of dementia per 1000 individuals treated with each 
antihypertensive drug class versus all other antihypertensive drug classes.
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weakening our instrument, as older prescriptions may be 
less relevant to the present patient. Our study may also have 
been subject to bias amplification, where the use of a weak 
instrument amplifies bias caused by violation of the indepen-
dence assumption.33 We have tried to minimize the effect of 
this phenomenon in our bias assessment by accounting for 
the instrumental variable analysis scaling factor. Further to 
this, our study may have misclassified the exposure due to 
the use of the intention-to-treat framework, which defines ex-
posure based on the first treatment prescribed. However, the 
benefits of this approach—such as preserving sample size 
and minimizing immortal time bias—outweigh the concerns. 
Related to misclassified exposures, there is also the potential 
for misclassified outcomes due to the difficulties associated 
with dementia diagnosis. This is less of a concern for the main 
analysis that considers all dementia subtypes together but 
should be considered when making inferences based on the 
dementia subtype analyses. Finally, this study does not make 
use of the time-to-event data available from the CPRD, which 
could be explored in the future using the instrumental variable 
estimation in a survival context models proposed by Tchetgen 
Tchetgen.58
CONCLUSIONS AND IMPLICATIONS
This study provides new evidence about the potential 
effects of antihypertensives on the risk of dementia through 
the novel application of non-genetic instrumental variable 
analysis to this research question. There were small differ-
ences in estimated effects on risk of dementia between drug 
classes. For example, we estimated that β-adrenoceptor block-
ers resulted in 13 (95% CI = 6, 20) fewer cases of any de-
mentia compared with other antihypertensive drugs per 1000 
people treated. However, we found that the magnitude of the 
differences between drug classes was smaller than many ob-
servational studies have previously reported. Future research 
should identify potential sources of unmeasured confound-
ing that may have affected previous observational studies to 
understand this inconsistency. This may also provide a stim-
ulus for more in-depth investigations of the related biolog-
ical mechanisms, which will in turn inform the study of both 
the disease process and potential drug targets for dementia 
prevention.
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